A company called Nastech was involved in developing intranasal formulations of drugs to treat a variety of different diseases. Dr Steven Quay was a founder of Nastech; he (and his colleagues, including Dr Alexis Leonard) filed several patent applications covering his inventions; some of these patents were subsequently licensed or acquired by other companies. One of these patent applications was for intranasal formulations of carbetocin (an oxytocin analog), for possible treatment of autism and other conditions.
What is the patent number of the US granted patent described above?
What is the number of the corresponding US published application?
Compare the claims in the granted patent vs. the published application. What is/are the major difference(s) between the claims in these two documents? (one or two sentences; hint: focus on Claim 1)
What is one key piece of translational research data presented in the patent documents that supports the claims? (one or two sentences; hint: do any of the “Examples” contain translational research data?)